Optimizing the use of gene expression profiling in early-stage breast cancer

Journal of Clinical Oncology

Volumn 34, Issue 36, 2016, Pages 4390-4397

  Kim, Hyun Seok ^a   Ashley, Cimino Mathews ^a   Maria, Cristina Figueroa Magalhaes ^a   Umbricht, Christopher B ^a   Illei, Peter B ^a   Cho, Soonweng ^a   Chowdhury, Nivedita ^a   Pesce, Catherine ^a   Jeter, Stacie C ^a   Mylander, Charles ^a   Rosman, Martin ^a   Tafra, Lorraine ^a   Turner, Bradley M ^a   Hicks, David G ^a   Jensen, Tyler A ^a   Miller, Dylan V ^a   Armstrong, Deborah K ^a   Connolly, Roisin M ^a   Fetting, John H ^a   Miller, Robert S ^a   Park, Ben Ho ^a   Stearns, Vered ^a   Visvanathan, Kala ^a   Wolff, Antonio C ^a   Cope, Leslie ^a   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ALGORITHM; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RISK; CANCER STAGING; CANCER TEST; CLINICAL DECISION MAKING; CLINICAL DECISION SUPPORT SYSTEM; CLINICAL PRACTICE; DISEASE ASSESSMENT; EARLY CANCER; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; ONCOTYPE DX RECURRENCE SCORE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RANDOM FOREST; RETROSPECTIVE STUDY; SCORING SYSTEM; VALIDATION STUDY; BREAST NEOPLASMS; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; GENETICS; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; STATISTICAL MODEL; TUMOR INVASION; UTILIZATION;

ADULT; AGED; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LINEAR MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 85009822960     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.7195     Document Type: Article

References (34)

1. International Breast Cancer Study Group (IBCSG): Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: Arandomized trial. J Natl Cancer Inst 94:1054-1065, 2002.
2. Wolff AC, Abeloff MD: Adjuvant chemotherapy for postmenopausal lymph node-negative breast cancer: It ain't necessarily so. J Natl Cancer Inst 94: 1041-1043, 2002.
3. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004.
4. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006.
5. Buyse M, Loi S, van't Veer L, et al: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183-1192, 2006.
6. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009.
7. Dowsett M, Sestak I, Lopez-Knowles E, et al: Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31: 2783-2790, 2013.
8. Sgroi DC, Sestak I, Cuzick J, et al: Prediction of late distant recurrence in patients with oestrogenreceptor- positive breast cancer: A prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the Trans- ATAC study population. Lancet Oncol 14:1067-1076, 2013.
9. Tang G, Shak S, Paik S, et al: Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 127:133-142, 2011.
10. Genomic Health: Invasive node-negative breast cancer. http://breast-cancer.oncotypedx.com/en-US/Managed-Care/Node-Negative.aspx.
11. Marchionni L, Wilson RF, Wolff AC, et al: Systematic review: Gene expression profiling assays in early-stage breast cancer. Ann Intern Med 148: 358-369, 2008.
12. Hassett MJ, Silver SM, Hughes ME, et al: Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 30:2218-2226, 2012.
13. Cardoso F, van't Veer LJ, Bogaerts J, et al: 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375: 717-729, 2016.
14. Sparano JA, Paik S: Development of the 21- gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26:721-728, 2008.
15. Breiman L: Random forests. Mach Learn 45: 5-32, 2001.
16. Liaw A, Wiener M: Classification and regression by randomForest. R News 2:18-22, 2002.
17. Shi T, Horvath S: Unsupervised learning with random forest predictors. J Comput Graph Stat 15: 118-138, 2006.
18. Maechler M, Rousseeuw P, Struyf A: Cluster: Cluster analysis basics and extensions. R package version 1.15.3, 2014.
19. Johns Hopkins University: Breast Cancer Recurrence Score Estimator. http://www.breastrecurrenceestimator.onc.jhmi.edu.
20. Carlson JJ, Roth JA: The impact of the Oncotype Dx breast cancer assay in clinical practice: A systematic review and meta-analysis. Breast Cancer Res Treat 141:13-22, 2013 [Erratum: Breast Cancer Res Treat 146:233, 2014].
21. Harris LN, Ismaila N, McShane LM, et al: Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 34:1134-1150, 2016.
22. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010.
23. Wolff AC, Hammond ME, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997-4013, 2013.
24. Wolff AC, Hammond ME, Hicks DG, et al: Reply to E.A. Rakha et al. J Clin Oncol 33:1302-1304, 2015.
25. Ingoldsby H, Webber M, Wall D, et al: Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis. Breast 22:879-886, 2013.
26. Allison KH, Kandalaft PL, Sitlani CM, et al: Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: Who does not always need testing? Breast Cancer Res Treat 131:413-424, 2012.
27. Mattes MD, Mann JM, Ashamalla H, et al: Routine histopathologic characteristics can predict oncotype DX recurrence score in subsets of breast cancer patients. Cancer Invest 31:604-606, 2013.
28. Tang P, Wang J, Hicks DG, et al: A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21- gene assay in breast cancer. Cancer Invest 28: 978-982, 2010.
29. Geradts J, Bean SM, Bentley RC, et al: The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest 28:969-977, 2010.
30. Flanagan MB, Dabbs DJ, Brufsky AM, et al: Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol 21:1255-1261, 2008.
31. Klein ME, Dabbs DJ, Shuai Y, et al: Prediction of the Oncotype DX recurrence score: Use of pathology-generated equations derived by linear regression analysis. Mod Pathol 26:658-664, 2013.
32. Gage MM, Rosman M, Mylander WC, et al: A Validated model for identifying patients unlikely to benefit from the 21-gene recurrence score assay. Clin Breast Cancer 15:467-472, 2015.
33. Turner BM, Skinner KA, Tang P, et al: Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. Mod Pathol 28:921-931, 2015.
34. Polley MY, Leung SC, Gao D, et al: An international study to increase concordance in Ki67 scoring. Mod Pathol 28:778-786, 2015.